Skip to main content
. Author manuscript; available in PMC: 2018 Jan 24.
Published in final edited form as: Mol Cancer Ther. 2017 Mar 14;16(6):1102–1113. doi: 10.1158/1535-7163.MCT-16-0314

Figure 4.

Figure 4

The recombinant hcc49scFv-Fas ligand (FasL) dramatically inhibits tumor growth of SAS cells with a low FasL/Fas ratio in vivo. A, An intratumoral injection of hcc49scFv-FasL (1 mg) twice daily suppressed the tumor growth of SAS cells in a subcutaneous implantation model. B, TUNEL assay of tissues derived from a tumor of SAS cells treated without (Vehicle) or with hcc49scFv-FasL for 10 days. C, The intraperitoneal administration of the hcc49scFv-FasL for 5 or 10 days was capable of inhibiting the tumor growth of SAS cells in an orthotropic model of OSCC.